Review articles cover how pre-MEASURE has impacted clinical decision-making and the interpretation of NPM1 MRD throughout the treatment course of AML. Other manuscripts address the limitations of ...

The company recently announced that its pivotal Phase 2 KOMET-001 trial in relapsed/refractory NPM1-mutated AML met ... and minimal residual disease (MRD) negativity in challenging AML frontline ...

We're preparing to commercialize ziftomenib as a potentially best-in-class menin inhibitor for patients with relapsed and/or refractory NPM1-mutant ... the trials to use MRD-negative CR and ...